18.8K
Articles
720.6K
Citations
3.1
avg. Impact Factor
316
h-index

Most Cited Articles of Department of Gynecologic Oncology and Reproductive Medicine in 2017

TitleJournalYearCitations
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell20172.1K
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology20171.4K
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manualCa-A Cancer Journal for Clinicians20171K
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialLancet Oncology, The2017981
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine2017978
Integrated genomic characterization of oesophageal carcinomaNature2017965
The Human Cell AtlasELife2017937
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell2017831
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet, The2017815
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the MicroenvironmentCancer Cell2017680
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell2017659
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood2017653
Association analysis identifies 65 new breast cancer risk lociNature2017643
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineScience2017577
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationNew England Journal of Medicine2017487
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionClinical Cancer Research2017460
2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extractionHeart Rhythm2017454
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceScience Translational Medicine2017409
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal MelanomaCancer Cell2017391
Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialLancet Oncology, The2017389
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy2017370
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyAnnals of Oncology2017361
GlioVis data portal for visualization and analysis of brain tumor expression datasetsNeuro-Oncology2017340
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialLancet Oncology, The2017318
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerNature Medicine2017316